Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) Read more about Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. Read more about Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry Read more about Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Read more about Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA Read more about A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA
Evaluation of S-600918 in Adults With Refractory Chronic Cough Read more about Evaluation of S-600918 in Adults With Refractory Chronic Cough
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). Read more about Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
Evaluation of the Asthma Management Program to Promote Activity for Students in Schools (Asthma-PASS) Read more about Evaluation of the Asthma Management Program to Promote Activity for Students in Schools (Asthma-PASS)
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Read more about Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors